In theory, any biomolecule (e.g., lipids, carbohydrates, proteins, and nucleic acids) capable of interacting with a specific metabolic or signaling pathway could be considered a drug target for the treatment of diseases or disease. Proteins are by far the most common targets, as they are the most structurally and functionally important biomolecules in living organisms. Antibodies are one of the promising therapeutic approaches because they can interact with biological targets with high affinity and specificity. Antibodies against almost all epitopes can be easily generated by phage display and hybridoma technology. Antibody targeting of intracellular epitopes enables the development of new antibody-based therapeutics as well as molecular tools for mechanistic studies. However, due to their hydrodynamic size and surface chemistry, antibodies cannot bypass cell membranes on their own. One of the solutions is to utilize vector-based delivery systems for intracellular protein delivery. CD BioSciences offers different in vivo delivery systems based on carrier materials to meet various needs of antibody delivery.

Figure 1. An overview of mRNA-based delivery of mAb. (Chung C, et al.; 2023)

CD BioSciences provides customized delivery strategies, through the precise design and modification of delivery vehicles, as well as advanced technology platforms, can help you solve:

• There is no suitable method for antibody delivery to specific tissues and organs in the body;
• Antibodies cannot easily cross cell membranes due to their size and surface chemistry
• Low payload of in vivo delivery systems
• Antibodies are diluted and degraded during in vivo delivery without protection
• Poor stability of antibody in vivo
• The release of antibodies in the body is uncontrolled
• Etc…

Key Features

Lipid Nanoparticles for Antibody Delivery

• Commercial Lipids

DOGS

DODAPL, DOPE

DPPC, DOTAP, Cholesterol, PEG2k-DSPE

DOPE, DOPC, Cholesterol

• Peptide Lipids

(C14)3(L)7(NH2)8, Stearyl-R8, Cholesteryl-GALA, DSPE-R4

• Aminoglycoside Lipid

DOSP

Polymers for Antibody Delivery

• Dendritic and multi-armed polymers

IgGMT

K- (PEG24-Ligand)-K-[K-(Stp4-C)2]2

• PEI and derivatives

PEI, pyridylthiourea- PEI

PEI

• Polyacrylic acids and polyacrylates

PPAAc

PMPC-b-PDPA, POEGMA-b-PDPA

• Polyesters and polyanhydrides

PEG-b-PCL-b-PDEA, PLGA

Poly(CPH-co-SA), poly(CPTEG-co-CPH)

• Polypeptides

PEG-pAsp(DET), pAsp(DET)

Polyarginine

• Polydisulfide

CPDs

• Polyoxanorbornene

MePh-b-dG

CPDs

Inorganic Nanoparticles

• Gold

AuNPs

Au-coated IONP

Au NCs

• Silica

Si NPs, core–shell RSNs, MSNs

Hypoxia-sensitive siNPs

• Carbon

OCBs

• Calcium phosphate

CaP NPs

Our Advantage:

• CD BioSciences can provide professional antibody in vivo delivery system to achieve efficient in vivo delivery;
• Our delivery system can add modified ligands to achieve targeting;
• The in vivo antibody delivery system has low toxicity to the body and is safe to use
• In vivo antibody delivery system Carriers protect antibodies from dilution and degradation during in vivo delivery
• The delivery system can achieve timing, location, fixed rate and targeted release in vivo, so that experimental animals have a long-lasting effect after a single injection
• The system load is high, and the delivery requirements of different doses can be fulfilled
• Professional design and service team to provide you with reliable service and technical support feedback technical report in time

CD BioSciences is focused on developing in vivo delivery systems using our core technologies. With our high-quality products and services, your delivery effect will be greatly improved. If you can't find the perfect in vivo delivery system, you can contact us. We can provide one-to-one personal customization services.

References

1. Yamin Li, et al.; Intracellular Antibody Delivery Mediated by Lipids, Polymers, and Inorganic Nanomaterials for Therapeutic Applications. Adv. Therap. 2020, 2000178.
2. Li Y, et al.; Intracellular Delivery of His-Tagged Genome-Editing Proteins Enabled by Nitrilotriacetic Acid-Containing Lipidoid Nanoparticles. Adv Healthc Mater. 2019 Mar;8(6): e1800996.
3. Okamoto T, Suzuki K. The Role of Gap Junction-Mediated Endothelial Cell-Cell Interaction in the Crosstalk between Inflammation and Blood Coagulation. Int J Mol Sci. 2017, 18(11):2254.
4. Bayele HK, et al.; Protein transduction by lipidic peptide dendrimers. J Pharm Sci. 2006, 95(6):1227-37.
5. Song Z, et al.; Synthetic polypeptides: from polymer design to supramolecular assembly and biomedical application. Chem Soc Rev. 2017, 46(21):6570-6599.
6. Probst CE, et al.; Quantum dots as a platform for nanoparticle drug delivery vehicle design. Adv Drug Deliv Rev. 2013, 65(5):703-18.
7. Anselmo AC, Mitragotri S. A Review of Clinical Translation of Inorganic Nanoparticles. AAPS J. 2015, 17(5):1041-54.
8. Chung C, et al.; Expanding the Reach of Monoclonal Antibodies: A Review of Synthetic Nucleic Acid Delivery in Immunotherapy. Antibodies (Basel). 2023,12(3):46.

* For research use only. Not for use in clinical diagnosis or treatment of humans or animals.